Post

New research · Oncology
Journal of Zhejiang University. Science. B · 4d
AI / informaticsJournal of Zhejiang University. Science. B · 2026

Machine learning-driven evaluation of protein kinase D3 as a co-diagnostic biomarker in hepatocellular carcinoma.

Jing Li, Yifan Zhao, Yicheng Ma … Linjing Li
Read paper
OncologyAI / informatics

Combined PRKD3 and clinical data improved hepatocellular carcinoma diagnostic accuracy.

Machine learning-driven evaluation of protein kinase D3 as a co-diagnostic biomarker in hepatocellular carcinoma.

Jing Li … Linjing Li
Journal of Zhejiang University. Science. B · 2026
Methods

To elucidate the diagnostic value and clinical relevance of protein kinase D3 (PRKD3) in hepatocellular carcinoma (hepatocellular carcinoma), we analyzed data retrieved from The Cancer Genome Atlas (TCGA) database, which revealed high expression of PRKD3 in hepatocellular carcinoma tissues.

n = 392 clinical plasma samples
0.861
Results
0.861
the combined model's improved ability to correctly diagnose liver cancer
n = 392 clinical plasma samples
More results

Subsequently, we collected a total of 392 clinical plasma samples from healthy individuals, patients with cirrhosis or decompensated cirrhosis, and patients with hepatocellular carcinoma.

Plasma PRKD3 levels were then determined across hepatocellular carcinoma patients and individuals at high risk of developing the disease.

More results

The results revealed significantly elevated PRKD3 concentrations in patients with cirrhosis, decompensated cirrhosis, and hepatocellular carcinoma compared to healthy controls ( P <0.01).

The areas under the receiver operating characteristic (ROC) curve for these three groups were 0.8107, 0.7899, and 0.7177, respectively.

“
Conclusion

Collectively, these findings highlight the potential of PRKD3 as an integral component of a comprehensive diagnostic tool for the early identification of hepatocellular carcinoma.

Read paper
0 comments

No comments yet. Be the first.

Related papers

LatestFoundational
Guideline
50 and 70 years of age
Australians within this age range are eligible for lung cancer screening
Review
80%
experts agreed on most questions about managing second breast cancer events
Guideline
“As more new targeted agents become available and hypomethylating agent-based triplet combinations are used more widely, we fully anticipate that we will, in some years' time, write a fourth guideline on the management of AML in older patients.”
Cohort Study
3.8-fold
Sickle cell disease recipients had 3.8-fold higher odds of DNA Damage Response-mutant clonal hematopoiesis.
Cross-sectional
1.3%
very few hospitals had a dedicated joint heart-and-cancer specialist team, despite broad support
Study
0.02
Average distance error of 0.02 mm between computed and physically measured locations
AI / Informatics
42
Number of individual research projects meeting eligibility and analyzed in this review
Cohort Study
65.3%
65.3% carried two copies of the valine version of the CD19 gene